Simultaneous Targeting of ATM and Mcl-1 Increases Cisplatin Sensitivity of Cisplatin-resistant Non-small Cell Lung Cancer

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2017 Jul 8

PMID 28686074

Citations 14

Authors

Fuquan Zhang

Mingjing Shen

Li Yang

Xiaodong Yang

Ying Tsai

Peter C Keng

Yongbing Chen

Soo Ok Lee

Yuhchyau Chen

Affiliations

Soon will be listed here.

Abstract

Development of cisplatin-resistance is an obstacle in non-small cell lung cancer (NSCLC) therapeutics. To investigate which molecules are associated with cisplatin-resistance, we analyzed expression profiles of several DNA repair and anti-apoptosis associated molecules in parental (A549P and H157P) and cisplatin-resistant (A549CisR and H157CisR) NSCLC cells. We detected constitutively upregulated nuclear ATM and cytosolic Mcl-1 molcules in cisplatin-resistant cells compared with parental cells. Increased levels of phosphorylated ATM (p-ATM) and its downstream molecules, CHK2, p-CHK2, p-53, and p-p53 were also detected in cisplatin-resistant cells, suggesting an activation of ATM signaling in these cells. Upon inhibition of ATM and Mcl-1 expression/activity using specific inhibitors of ATM and/or Mcl-1, we found significantly enhanced cisplatin-cytotoxicity and increased apoptosis of A549CisR cells after cisplatin treatment. Several A549CisR-derived cell lines, including ATM knocked down (A549CisR-siATM), Mcl-1 knocked down (A549CisR-shMcl1), ATM/Mcl-1 double knocked down (A549CisR-siATM/shMcl1) as well as scramble control (A549CisR-sc), were then developed. Higher cisplatin-cytotoxicity and increased apoptosis were observed in A549CisR-siATM, A549CisR-shMcl1, and A549CisR-siATM/shMcl1 cells compared with A549CisR-sc cells, and the most significant effect was shown in A549CisR-siATM/shMcl1 cells. In in vivo mice studies using subcutaneous xenograft mouse models developed with A549CisR-sc and A549CisR-siATM/shMcl1 cells, significant tumor regression in A549CisR-siATM/shMcl1 cells-derived xenografts was observed after cisplatin injection, but not in A549CisR-sc cells-derived xenografts. Finally, inhibitor studies revealed activation of Erk signaling pathway was most important in upregulation of ATM and Mcl-1 molcules in cisplatin-resistant cells. These studies suggest that simultaneous blocking of ATM/Mcl-1 molcules or downstream Erk signaling may recover the cisplatin-resistance of lung cancer.

Citing Articles

The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients.

Abrehdari-Tafreshi Z, Arefian E, Rakhshani N, Najafi S Biochem Genet. 2024; 62(6):4929-4951.

PMID: 38379036 DOI: 10.1007/s10528-024-10740-6.

Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer.

Dera A, Zaib S, Areeba , Hussain N, Rana N, Javed H Molecules. 2023; 28(12).

PMID: 37375404 PMC: 10304665. DOI: 10.3390/molecules28124850.

Silence of URI in gastric cancer cells promotes cisplatin-induced DNA damage and apoptosis.

Bian H, Gu Y, Chen C, Chen J, Zhang F, Xu Z Am J Cancer Res. 2023; 13(3):936-949.

PMID: 37034221 PMC: 10077030.

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance.

Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi P Cancers (Basel). 2022; 14(19).

PMID: 36230484 PMC: 9558974. DOI: 10.3390/cancers14194562.

A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma.

Meng Z, Yang W, Zhu L, Liu W, Wang Y Front Pharmacol. 2022; 13:963072.

PMID: 36016575 PMC: 9395581. DOI: 10.3389/fphar.2022.963072.

References

Huen M, Chen J . The DNA damage response pathways: at the crossroad of protein modifications. Cell Res. 2007; 18(1):8-16. DOI: 10.1038/cr.2007.109. View

Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T . BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015; 113(3):425-32. PMC: 4522629. DOI: 10.1038/bjc.2015.220. View

Parsons A, Daley A, Begh R, Aveyard P . Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010; 340:b5569. PMC: 2809841. DOI: 10.1136/bmj.b5569. View

Epling-Burnette P, Zhong B, Bai F, Jiang K, Bailey R, Garcia R . Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol. 2001; 166(12):7486-95. DOI: 10.4049/jimmunol.166.12.7486. View

Buscemi G, Ricci C, Zannini L, Fontanella E, Plevani P, Delia D . Bimodal regulation of p21(waf1) protein as function of DNA damage levels. Cell Cycle. 2014; 13(18):2901-12. PMC: 4615108. DOI: 10.4161/15384101.2014.946852. View

Song L, Coppola D, Livingston S, Cress D, Haura E . Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther. 2005; 4(3):267-76. DOI: 10.4161/cbt.4.3.1496. View

Goodrum F, Ornelles D . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol. 1998; 72(12):9479-90. PMC: 110444. DOI: 10.1128/JVI.72.12.9479-9490.1998. View

Lai S, Hwang J, Perng R, Whang-Peng J . Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncol Res. 1995; 7(1):31-8. View

Zhang T, Shen Y, Chen Y, Hsieh J, Kong Z . The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect. Int J Radiat Biol. 2015; 91(4):368-78. DOI: 10.3109/09553002.2015.1001531. View

10.

Abulwerdi F, Liao C, Liu M, Azmi A, Aboukameel A, Mady A . A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2013; 13(3):565-75. PMC: 4174574. DOI: 10.1158/1535-7163.MCT-12-0767. View

11.

Smith J, Tho L, Xu N, Gillespie D . The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108:73-112. DOI: 10.1016/B978-0-12-380888-2.00003-0. View

12.

Kim W, Rajasekaran B, Brown K . MLH1- and ATM-dependent MAPK signaling is activated through c-Abl in response to the alkylator N-methyl-N'-nitro-N'-nitrosoguanidine. J Biol Chem. 2007; 282(44):32021-31. DOI: 10.1074/jbc.M701451200. View

13.

Rainey M, Charlton M, Stanton R, Kastan M . Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008; 68(18):7466-74. PMC: 2559948. DOI: 10.1158/0008-5472.CAN-08-0763. View

14.

Eliezer Y, Argaman L, Kornowski M, Roniger M, Goldberg M . Interplay between the DNA damage proteins MDC1 and ATM in the regulation of the spindle assembly checkpoint. J Biol Chem. 2014; 289(12):8182-93. PMC: 3961647. DOI: 10.1074/jbc.M113.532739. View

15.

Shiloh Y, Ziv Y . The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013; 14(4):197-210. DOI: 10.1038/nrm3546. View

16.

Albarakati N, Abdel-Fatah T, Doherty R, Russell R, Agarwal D, Moseley P . Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol. 2014; 9(1):204-17. PMC: 5528668. DOI: 10.1016/j.molonc.2014.08.001. View

17.

Persons D, Yazlovitskaya E, Cui W, Pelling J . Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res. 1999; 5(5):1007-14. View

18.

Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki J . Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. Biochem Pharmacol. 2014; 89(3):361-9. DOI: 10.1016/j.bcp.2014.03.008. View

19.

Basu A, Krishnamurthy S . Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010; 2010. PMC: 2929606. DOI: 10.4061/2010/201367. View

20.

Pei X, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L . Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS One. 2014; 9(3):e89064. PMC: 3942309. DOI: 10.1371/journal.pone.0089064. View